MissionIR Articles
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for…
-
EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Poised to Execute Rapid Growth Strategy; Announces Acquisition of 50% Stake in Project Radius in Ontario
EverGen appears poised to deliver on its rapid growth strategy and solidify its market position within the RNG space Company announced acquisition of 50% stake of Ontario’s Project Radius, following recently announced plans to acquire…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO Discusses UST(TM) Platform, Early Access Program on Stock Day Podcast
Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences markets and other industries. The company…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022,…
-
MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Scheduled Earnings Conference Call
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, will host an earnings conference call, during which the company will announce and…
-
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients
A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM) Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”) Lexaria…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Demonstrates AI Drone Threat Detection in U.S. Army Live Fire Exercise
- MissionIRNewsBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Enters Strategic Cooperation With AIBO Robotics to Advance AI-Driven Automation and Smart Mobility
- Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications